This clinical trial is focused on studying the effectiveness and safety of a treatment for Acute Myeloid Leukemia (AML), a type of cancer that affects the blood and bone marrow. The treatment being tested is called Mocravimod (KRP203), which is taken in the form of capsules. The study involves patients with AML who are undergoing a procedure known as allogeneic hematopoietic cell transplantation (HCT), which is a type of stem cell transplant that uses cells from a donor to help restore the patient’s bone marrow.

The purpose of the study is to compare the effects of Mocravimod with a placebo, which is a substance with no active medication. Participants in the study will be randomly assigned to receive either Mocravimod or the placebo. The study will monitor the participants over a period to assess how well the treatment works in preventing the return of cancer and improving survival rates. The study will also look at the treatment’s impact on conditions like Graft-versus-Host Disease (GvHD), which can occur after a transplant when the donor’s cells attack the recipient’s body.

Throughout the study, participants will receive regular check-ups and monitoring to ensure their safety and to gather data on the treatment’s effectiveness. The study aims to provide valuable information on whether Mocravimod can be a beneficial addition to the treatment plan for patients with AML undergoing HCT.